US 11,958,846 B2
Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
Christopher Adair, Woodstock (CA); Katsumasa Nakajima, Winchester, MA (US); Rukundo Ntaganda, Cambridge, MA (US); Julien Papillon, Somerville, MA (US); and Troy Douglas Smith, Nashua, NH (US)
Assigned to Novartis AG, Basel (CH)
Appl. No. 17/268,512
Filed by Novartis AG, Basel (CH)
PCT Filed Aug. 12, 2019, PCT No. PCT/IB2019/056847
§ 371(c)(1), (2) Date Feb. 15, 2021,
PCT Pub. No. WO2020/035779, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/765,138, filed on Aug. 17, 2018.
Prior Publication US 2021/0323956 A1, Oct. 21, 2021
Int. Cl. C07D 417/12 (2006.01); A61K 45/06 (2006.01)
CPC C07D 417/12 (2013.01) [A61K 45/06 (2013.01)] 11 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, of formula I:

OG Complex Work Unit Chemistry
in which:
R1 is selected from hydrogen, amino and hydroxy-substituted C1-2 alkyl;
R2 is hydrogen;
R3 is selected from C1-2 alkyl and halo-substituted-C1-2 alkyl;
R4 is hydrogen;
R5 is selected from hydrogen and halo; and
R6 is selected from hydrogen and halo.